文献速递乳腺癌放疗

大分割区域淋巴结照射在乳腺癌患者中的疗效与毒性

The Efficacy and Toxicity of Hypofractionated Regional Nodal Irradiation in Breast Cancer Patients.
PubMed 文献 · Pract Radiat Oncol · 2025-04-29

该回顾性分析纳入154例接受大分割区域淋巴结照射(HF-RNI)的淋巴结阳性或高危淋巴结阴性乳腺癌患者,中位剂量40 Gy/16次,中位随访65.4个月。结果显示慢性臂丛神经病发生率2.0%、上肢淋巴水肿10.5%,晚期心脏和肺毒性率分别为0.7%和3.3%,5年无局部复发生存率98.0%、无区域复发生存率99.3%、无病生存率90.1%、总生存率88.1%。结论认为HF-RNI慢性毒性低且疾病控制优异,支持更广泛临床应用,但需随机试验长期结果确认。

要点

  • HF-RNI后慢性臂丛神经病2.0%、上肢淋巴水肿10.5%,晚期心脏毒性0.7%、肺毒性3.3%。
  • 5年LRFS 98.0%、RRFS 99.3%、DFS 90.1%、OS 88.1%,疾病控制优异。
  • 中位剂量40 Gy/16次,支持HF-RNI临床推广,但需随机试验长期证据。

核心结论

  • HF-RNI表现出低慢性毒性率和优异疾病控制,支持更广泛临床应用,但需随机试验长期结果确认。

研究设计与样本

  • 回顾性分析纳入154例淋巴结阳性或高危淋巴结阴性乳腺癌患者,2008至2020年接受HF-RNI(>2 Gy/次)。
  • 中位剂量40 Gy/16次,照射乳腺/胸壁/重建乳腺及区域淋巴结;主要终点为慢性毒性发生率。

主要发现

  • 中位随访65.4个月(范围4-170个月),中位年龄58岁(IQR 48.3-71.0)。
  • 慢性臂丛神经病2.0%、活动范围受限1.3%、上肢淋巴水肿10.5%;晚期心脏毒性0.7%、肺毒性3.3%。
  • 5年LRFS 98.0%、RRFS 99.3%、DFS 90.1%、OS 88.1%。

关键数值与推荐

  • HF-RNI定义为>2 Gy/次;中位剂量40 Gy/16次。
  • 前哨淋巴结活检49.4%、腋窝淋巴结清扫47.4%、未行腋窝手术3.2%。
  • RNI靶区包括锁骨上及腋窝1-3级淋巴结者65.6%,仅锁骨上及3级者34.4%,内乳淋巴结照射7例(4.7%)。

临床怎么用

  • 对淋巴结阳性或高危淋巴结阴性乳腺癌患者,HF-RNI可作为区域淋巴结照射方案,慢性毒性低且疾病控制良好。

局限性

  • 回顾性 design,样本量154例,需随机试验长期结果提供确定性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Regional nodal irradiation (RNI) is increasingly used in place of axillary lymph node dissection (ALND) in carefully selected breast cancer patients. Although hypofractioned whole breast irradiation is standard for node-negative disease, long-term data on hypofractionated RNI (HF-RNI) are limited. This study aims to assess the long-term safety and effectiveness of HF-RNI for breast cancer patients. METHODS AND MATERIALS: This retrospective analysis included 154 patients with node-positive or high-risk node-negative breast cancer treated with HF-RNI (>2 Gy/fraction) between 2008 and 2020. Median dose was 40 Gy/16 fractions to the breast, chest wall, or reconstructed breast as well as regional nodes. The primary endpoint was the incidence of chronic toxicity. Secondary endpoints were acute toxicity, local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), disease-free survival (DFS), and overall survival (OS). Acute toxicities were defined as those occurring during radiation therapy or within 90 days post-treatment; chronic toxicities were defined as those persisting or arising at least 180 days after radiation completion. RESULTS: Median follow-up was 65.4 months (range, 4-170 months). Median age was 58 years (interquartile range, 48.3-71.0). Sentinel lymph node biopsy was performed in 49.4% of patients, 47.4% underwent ALND, and 3.2% had no axillary surgery. RNI targets included supraclavicular and axillary level 1 to 3 nodes in 65.6% of patients, whereas 34.4% were treated only to the supraclavicular and level 3 nodes. There were 7 (4.7%) patients that had internal mammary nodes treated. Chronic brachial plexopathy occurred in 2.0% of patients, limited range of motion in 1.3%, and upper extremity lymphedema in 10.5%. Late cardiac and lung toxicity rates were low at 0.7% and 3.3%, respectively. Five-year actuarial rates of LRFS, RRFS, DFS, and OS were 98.0%, 99.3%, 90.1%, and 88.1%, respectively. CONCLUSIONS: HF-RNI demonstrates low rates of chronic toxicity and excellent disease control, supporting wider adoption in clinical practice. Long-term results of randomized trials of HF-RNI are needed for definitive evidence.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Spiegel DY, Willcox J, Levey J, et al. The Efficacy and Toxicity of Hypofractionated Regional Nodal Irradiation in Breast Cancer Patients. Pract Radiat Oncol. 2025. PMID: 40311918. doi:10.1016/j.prro.2025.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。